Cyclooxygenase Inhibitors
"Cyclooxygenase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
Descriptor ID |
D016861
|
MeSH Number(s) |
D27.505.519.389.310 D27.505.696.663.850.014.040.500.500 D27.505.954.158.030.500 D27.505.954.329.030.500
|
Concept/Terms |
Cyclooxygenase Inhibitors- Cyclooxygenase Inhibitors
- Inhibitors, Cyclo-Oxygenase
- Inhibitors, Cyclo Oxygenase
- Inhibitors, Cyclooxygenase
- Prostaglandin Synthesis Antagonists
- Antagonists, Prostaglandin Synthesis
- Inhibitors, Prostaglandin-Endoperoxide Synthase
- Inhibitors, Prostaglandin Endoperoxide Synthase
- Prostaglandin Endoperoxide Synthase Inhibitors
- Prostaglandin Synthase Inhibitors
- Cyclo-Oxygenase Inhibitors
- Cyclo Oxygenase Inhibitors
- Inhibitors, Prostaglandin Synthase
|
Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase Inhibitors".
This graph shows the total number of publications written about "Cyclooxygenase Inhibitors" by people in this website by year, and whether "Cyclooxygenase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 1 | 0 | 1 |
1996 | 2 | 1 | 3 |
1998 | 0 | 1 | 1 |
1999 | 3 | 3 | 6 |
2000 | 7 | 5 | 12 |
2001 | 4 | 2 | 6 |
2002 | 13 | 8 | 21 |
2003 | 9 | 6 | 15 |
2004 | 18 | 5 | 23 |
2005 | 7 | 11 | 18 |
2006 | 3 | 1 | 4 |
2007 | 5 | 5 | 10 |
2008 | 1 | 2 | 3 |
2009 | 0 | 6 | 6 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2015 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
2020 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclooxygenase Inhibitors" by people in Profiles.
-
Prescribing Trend of Inappropriate Medications in Outpatient Clinics for Older Adults With Heart Failure in the United States: NAMCS 2012 to 2016. Am J Cardiol. 2021 08 01; 152:168.
-
Maternal low body mass index is a risk factor for fetal ductal constriction following indomethacin use among women undergoing fetal repair of spina bifida. Prenat Diagn. 2020 05; 40(6):669-673.
-
Changes in the Diagnosis and Management of Patent Ductus Arteriosus from 2006 to 2015 in United States Neonatal Intensive Care Units. J Pediatr. 2017 10; 189:105-112.
-
Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017 06; 36(2):289-303.
-
Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase. Bioorg Med Chem. 2017 02 01; 25(3):1202-1218.
-
Automated identification of an aspirin-exacerbated respiratory disease cohort. J Allergy Clin Immunol. 2017 Mar; 139(3):819-825.e6.
-
Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol. 2016 Feb; 43(1):65-77.
-
Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants. J Neonatal Perinatal Med. 2014 Jan 01; 7(3):229-35.
-
The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology. 2012 Jul-Aug; 12(4):372-9.
-
Prevention. Aspirin in primary prevention--good news and bad news. Nat Rev Cardiol. 2012 02 28; 9(5):262-3.